FindTrial
Sign In

Effects of Rosiglitazone on Serum Ghrelin and Peptide YY Levels

Effects of Rosiglitazone on Serum Ghrelin and Peptide YY Levels in Diabetic Women

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00522470
Enrollment
Unknown
Registered
2007-08-29
Start date
Unknown
Completion date
Unknown
Last updated
2008-05-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity, Type 2 Diabetes Mellitus

Brief summary

We aimed to evaluate the effects of rosiglitazone on serum ghrelin and peptide yy levels in diabetic women.

Interventions

DRUGrosiglitazone

Sponsors

Baskent University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
45 Years to 65 Years

Inclusion criteria

* newly diagnosed, drug naive women with type 2 diabetes

Exclusion criteria

* presence of severe cardiovascular disease (eg, New York Heart Association class III or IV congestive heart failure or a history of myocardial infarction or stroke) * presence of thyroid, pituitary, nutritional, hepatic, renal, or neoplastic disorders

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026